Prize fight in Paris: Alnylam and Ionis slug it out over PhIII data in preparation for a blockbuster showdown
This morning Alnylam $ALNY rolled out a battery of stellar Phase III data on their blockbuster contender patisiran, which promises to go on to become the company’s first approved and marketed drug after 15 long years of RNAi discovery and development work. And as of now, it looks like they’ll be going head-to-head with the antisense experts at Ionis $IONS, the underdogs in what promises to be a long running fight for a small group of patients suffering from rare cases of hereditary ATTR (hATTR) amyloidosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.